[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622468":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":29,"id":54,"slug":29,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":29,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":29,"enrollmentInfo":62,"targetDuration":29,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":38,"whyStopped":29,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Rambam Health Care Campus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Chronic metamizole users","EXPERIMENTAL","Patients receiving Optalgin prior to study enrollment",[13],"Drug: metamizole",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2: New metamizole users","Patients receiving Optalgin after to study enrollment",[13],[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","metamizole","chronic metamizole use",[9,15],[25],"OPTALGIN",{"type":20,"name":21,"description":27,"armGroupLabels":28,"otherNames":29},"New metamizole users",[9,15],null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"Liat Rappaport","CONTACT","+97247776234","o_trials@rambam.health.gov.il",[37],{"facility":5,"status":38,"city":39,"state":29,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Haifa","31096","Israel",{"type":43,"coordinates":44},"Point",[45,46],34.99928,32.81303,{"lat":46,"lon":45},[49],{"name":29,"role":33,"phone":50,"phoneExt":29,"email":51},"047776724","g_froumin@rambam.health.gov.il",{"type":53,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100622468",false,"NCT07384013","Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","Inclusion Criteria:\n\n* Adult oncology patients (≥18 years old).\n* Receiving apixaban or rivaroxaban for anticoagulation.\n* New\u002Fcurrent metamizole users taking at least 1g TID for pain management.\n* Platelets ≥100×10⁹\u002FL\n* ECOG PS\\\u003C3\n* Provided informed consent\n\nExclusion Criteria:\n\n* History of allergic reaction to metamizole or DOACs.\n* Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT\u002Fzonda)","ALL","18 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"NA","Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)",[70,71,72],"Oncologic Diseases","Coagulation Defect","Pain Management",[74,75],"Direct Oral Anticoagulants (DOACs)","Optalgin","2026-01-26",{"date":78,"type":79},"2026-02-03","ACTUAL",{"date":81,"type":79},"2025-11-01",{"date":83,"type":64},"2027-12-31",{"name":5,"class":6},1]